Compare Stocks → Wall Street Legend Warns: 'A Strange Day Is Coming to America' (From Chaikin Analytics) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:LUCDNASDAQ:MDAINASDAQ:MODDNYSE:RVP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUCDLucid Diagnostics$0.90-1.1%$0.90$0.63▼$1.85$47.02M1.48165,388 shs101,591 shsMDAISpectral AI$1.61-0.6%$1.96$1.54▼$19.50$28.14M0.611.45 million shs311,475 shsMODDModular Medical$1.58-0.6%$1.69$0.84▼$2.22$34.60M0.5155,775 shs12,907 shsRVPRetractable Technologies$0.94$1.09$0.87▼$1.34$28.11M2.1183,287 shs57,618 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUCDLucid Diagnostics0.00%-1.52%+34.08%-27.88%-38.94%MDAISpectral AI0.00%-11.96%-12.43%-17.35%+161,999,900.00%MODDModular Medical0.00%-7.02%+0.63%-4.22%+44.55%RVPRetractable Technologies0.00%+4.16%-12.49%-27.08%-20.95%Wall Street Legend Warns: "A Strange Day Is Coming to America" (Ad)Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making.Click here to learn more.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLUCDLucid Diagnostics3.0169 of 5 stars3.55.00.00.04.01.70.0MDAISpectral AI4.1858 of 5 stars3.52.00.00.03.55.00.0MODDModular Medical1.7063 of 5 stars3.53.00.00.02.11.70.0RVPRetractable TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLUCDLucid Diagnostics3.00Buy$2.75204.78% UpsideMDAISpectral AI3.00Buy$4.00148.45% UpsideMODDModular Medical3.00Buy$4.25168.99% UpsideRVPRetractable TechnologiesN/AN/AN/AN/ACurrent Analyst RatingsLatest RVP, MDAI, LUCD, and MODD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2024LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$3.005/13/2024LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.504/12/2024LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.503/27/2024LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$3.80 ➝ $3.003/27/2024LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.503/21/2024MODDModular MedicalBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$5.00(Data available from 5/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLUCDLucid Diagnostics$2.43M19.35N/AN/A($0.47) per share-1.92MDAISpectral AI$18.06M1.56N/AN/A($0.10) per share-16.10MODDModular MedicalN/AN/AN/AN/A$0.46 per shareN/ARVPRetractable Technologies$43.60M0.64$0.02 per share54.68$3.31 per share0.28Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLUCDLucid Diagnostics-$52.67M-$1.27N/A∞N/A-1,576.60%-901.79%-106.33%8/12/2024 (Estimated)MDAISpectral AI-$20.85MN/A0.00∞N/AN/AN/A-108.45%8/6/2024 (Estimated)MODDModular Medical-$13.88M-$0.97N/A∞N/AN/A-235.93%-180.37%6/24/2024 (Estimated)RVPRetractable Technologies-$7.01M-$0.26N/A∞N/A-18.84%-7.55%-4.18%N/ALatest RVP, MDAI, LUCD, and MODD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024Q1 2024RVPRetractable TechnologiesN/A$0.01+$0.01$0.01N/A$7.60 million5/7/2024Q1 2024MDAISpectral AIN/A-$0.19-$0.19-$0.19N/A$6.33 million3/29/2024Q4 2023MDAISpectral AIN/A-$0.22-$0.22-$0.22N/A$5.29 million 3/26/2024Q4 2023LUCDLucid DiagnosticsN/A-$0.26-$0.26-$0.26N/A$1.04 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLUCDLucid DiagnosticsN/AN/AN/AN/AN/AMDAISpectral AIN/AN/AN/AN/AN/AMODDModular MedicalN/AN/AN/AN/AN/ARVPRetractable TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLUCDLucid DiagnosticsN/A1.381.36MDAISpectral AIN/A0.850.84MODDModular MedicalN/A1.631.63RVPRetractable Technologies0.0111.028.18OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLUCDLucid Diagnostics74.01%MDAISpectral AI67.08%MODDModular Medical27.47%RVPRetractable Technologies7.58%Insider OwnershipCompanyInsider OwnershipLUCDLucid Diagnostics4.80%MDAISpectral AI56.73%MODDModular Medical32.34%RVPRetractable Technologies54.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableLUCDLucid Diagnostics7052.11 million49.61 millionNo DataMDAISpectral AI7817.48 million7.56 millionNot OptionableMODDModular Medical3721.90 million14.82 millionNot OptionableRVPRetractable Technologies14829.94 million13.59 millionOptionableRVP, MDAI, LUCD, and MODD HeadlinesRecent News About These CompaniesMay 28 at 3:22 AM | americanbankingnews.comRetractable Technologies (NYSE:RVP) Research Coverage Started at StockNews.comMay 23, 2024 | insidertrades.comRetractable Technologies, Inc. (NYSE:RVP) CEO Buys $18,000.00 in StockMay 21, 2024 | insidertrades.comRetractable Technologies, Inc. (NYSE:RVP) CEO Thomas J. Shaw Acquires 48,635 SharesMay 15, 2024 | msn.comRVP Stock Earnings: Retractable Technologies Reported Results for Q1 2024May 15, 2024 | finance.yahoo.comRetractable Technologies, Inc. Results for the Period Ended March 31, 2024May 15, 2024 | sfgate.comRetractable Technologies: Q1 Earnings SnapshotApril 19, 2024 | insidertrades.comRetractable Technologies, Inc. (NYSE:RVP) CEO Thomas J. Shaw Buys 15,363 SharesApril 17, 2024 | benzinga.comRetractable Technologies And 2 Other Penny Stocks Insiders Are BuyingApril 10, 2024 | uk.investing.comRetractable Technologies CEO acquires $46.4k in stockApril 8, 2024 | investorplace.comRVP Stock Earnings: Retractable Technologies Reported Results for Q4 2023March 29, 2024 | businesswire.comRetractable Technologies, Inc. Reports Results for 2023March 29, 2024 | businesswire.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 28, 2024 | msn.comJourney Medical And 2 Other Stocks Under $4 Insiders Are BuyingMarch 27, 2024 | msn.comRetractable Technologies And 3 Other Stocks Under $4 Insiders Are BuyingMarch 18, 2024 | msn.comTraeger And 3 Other Stocks Under $5 Insiders Are BuyingMarch 17, 2024 | uk.investing.comRetractable Technologies CEO acquires $6k in company stockMarch 14, 2024 | edition.cnn.comRetractable Technologies, Inc.March 13, 2024 | msn.comBrightcove And 2 Other Stocks Under $3 Insiders Are BuyingMarch 11, 2024 | benzinga.com$1.5M Bet On This Penny Stock? Check Out These 4 Stocks Under $5 Insiders Are Aggressively BuyingFebruary 24, 2024 | barrons.comRetractable Technologies Inc.New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsLucid DiagnosticsNASDAQ:LUCDLucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Spectral AINASDAQ:MDAISpectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.Modular MedicalNASDAQ:MODDModular Medical, Inc. operates as a development stage medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for diabetes. The company was founded in 1998 and is headquartered in San Diego, California.Retractable TechnologiesNYSE:RVPRetractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.